This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

CREST Syndrome — Limited Cutaneous Systemic Sclerosis크레스트증후군 (CREST증후군)

Contents and key points
ItemDetails
A. Classification codesICD-10: M34.1 (CREST syndrome) | Special Copayment Reduction: V138 (rare disease)
B. SynonymsCREST syndrome | Combination of calcinosis·Raynaud phenomenon·esophageal dysmotility·sclerodactyly·telangiectasia (CREST = Calcinosis cutis, Raynaud phenomenon, Esophageal dysmotility, Sclerodactyly, Telangiectasia)
C. Adult onsetLikelihood of first onset in adulthood very high — CREST syndrome (limited cutaneous systemic sclerosis) is typically first diagnosed in middle-aged adults in their 40s~60s. Raynaud phenomenon often precedes it by years to decades, so a course in which only Raynaud phenomenon is present in young adulthood and CREST findings become established in middle age is common. Pediatric onset is very rare.
1. History1964: Winterbauer described the 5 CREST findings → 1975: the CREST acronym established by Velayos et al. → 1988: LeRoy established the limited cutaneous subtype (lcSSc) classification → 2013: integrated into the ACR/EULAR criteria.
2. CausesComplex pathogenesis of autoimmunity (anti-centromere antibodies), vascular abnormalities (small vessel endothelial injury), and fibrosis. Environmental factors (silica, organic solvents), HLA susceptibility alleles. Exact single cause unknown.
3. GeneticsAnti-centromere antibodies (ACA) associated with HLA-DQB1*05:01, DRB1*01:01, DRB1*04:04. Associations with IRF5, STAT4, TNFSF4 SNPs. Polygenic complex inheritance. Familial clustering weak but present.
4. General epidemiologylcSSc/CREST accounts for about 60~70% of systemic sclerosis. Female:male about 4~6:1. Most common in the 40s~60s. Overlap with primary biliary cirrhosis (PBC) about 5%. Anti-centromere antibody positive in about 70~80%.
5. PathophysiologySmall vessel endothelial injury → vasoconstriction (endothelin-1↑, NO↓) → ischemia·reperfusion → calcium deposition (calcinosis). Anti-centromere antibodies → damage to the mitotic spindle → promotion of apoptosis. TGF-β → fibroblast activation → limited fibrosis.
6. SymptomsC: calcinosis cutis (fingers·elbows·knees) | R: Raynaud phenomenon | E: esophageal dysphagia·reflux | S: sclerodactyly (skin sclerosis of the fingers) | T: telangiectasia (face·hands·mucosa). Late PAH and primary biliary cirrhosis may be present.
7. SignsPalpable subcutaneous calcified nodules at the fingertips, sclerodactyly, mucosal·facial telangiectasias (blanching with pressure), SD pattern on nailfold capillaroscopy, positive anti-centromere antibodies, accentuated P2 with PAH.
8. ScreeningIn patients with Raynaud phenomenon, ANA·anti-centromere antibodies and nailfold capillaroscopy. Annual echocardiography (PAH screening), pulmonary function tests. Screening for primary biliary cirrhosis when ALP·GGT are elevated.
9. DiagnosisApply the 2013 ACR/EULAR classification criteria. Sum of items such as positive anti-centromere antibodies (3 points), capillaroscopy abnormalities (2 points), Raynaud phenomenon (3 points), telangiectasia (2 points), PAH (2 points). Soft tissue calcification confirmed on hand X-ray.
10. TreatmentRaynaud: CCB, PDE-5 inhibitors. PAH: ERA+PDE-5 inhibitor combination, prostacyclin. GERD: long-term PPI. Calcinosis: colchicine, low-dose warfarin (limited evidence), laser·surgical excision. Skin: moisturizing, physical therapy.
11. PrognosisBetter than diffuse (dcSSc). 10-year survival about 75~85%. Main causes of death: PAH (median survival 3~5 years after diagnosis, improved with targeted therapy), liver failure with coexisting primary biliary cirrhosis. Skin involvement is stable.
12. PreventionPrimary: reduce silica·organic solvent exposure, smoking cessation. Secondary: early autoantibody·capillaroscopy screening in Raynaud phenomenon. Tertiary: annual PAH screening (echocardiography), PFT, cold avoidance, joint·skin protection education.
13. ReferencesVelayos EE, et al. The 'CREST' syndrome. Semin Arthritis Rheum. 1979 … and 9 other papers

1. History

The history of CREST syndrome stems from attempts in the mid-20th century to precisely classify the clinical subtypes of systemic sclerosis. From the 19th century, a group of scleroderma patients was observed whose skin sclerosis was limited to the hands and fingers and who showed characteristic visceral findings, but it was in the 20th century that this was systematized as an independent subtype. In 1964, the American physician Richard Winterbauer described in detail a group of patients in whom five findings—calcinosis cutis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia—appeared together, emphasizing that this combination was a clinical entity distinct from diffuse systemic sclerosis.

In 1975, Velayos et al. formalized the acronym 'CREST,' combining the English initials of the five characteristic findings, and this name began to be used internationally. The CREST acronym was intuitive for both clinicians and patients and was widely used, and during the 1970s~80s, anti-centromere antibody (ACA) was shown to be specifically positive in this syndrome, greatly improving diagnostic accuracy. The discovery of ACA was a landmark turning point that made immunological subtyping of systemic sclerosis possible.

In 1988, LeRoy and colleagues proposed a system classifying systemic sclerosis by the extent of skin sclerosis into diffuse cutaneous SSc (dcSSc) and limited cutaneous SSc (lcSSc), and CREST syndrome was redefined as the core clinical expression of lcSSc. This classification system reflects differences in clinical course, prognosis, and patterns of visceral involvement and is used worldwide to this day. Regarding the CREST acronym, it is emphasized that lcSSc is the more comprehensive concept, since the limited subtype of systemic sclerosis can be diagnosed even if not all 5 findings are present.

The revised classification criteria jointly published by ACR and EULAR in 2013 evaluate dcSSc and lcSSc in an integrated scoring system and reflect the clinical findings of CREST syndrome in the criteria by including telangiectasia, capillaroscopy abnormalities, and anti-centromere antibodies. In Korea, cohorts of systemic sclerosis patients including CREST syndrome have been established, centered on the Korean College of Rheumatology, and designation for Special Copayment Reduction (V138) has reduced patients' medical cost burden. Recently, as PAH has emerged as a major cause of death in patients with CREST syndrome, the importance of systematic PAH early detection programs such as the DETECT algorithm has been emphasized.

Regarding terminology, current international guidelines recommend 'limited cutaneous systemic sclerosis (lcSSc)' as the official name instead of 'CREST syndrome,' but in clinical practice and the Korean insurance system the expression CREST syndrome is still used alongside it. In ICD-10, it is assigned an independent code, M34.1, which is used in practice.


2. Causes

The cause of CREST syndrome (limited cutaneous systemic sclerosis, lcSSc), as with progressive systemic sclerosis in general, is a multifactorial pathogenesis in which autoimmunity, vascular abnormalities, and fibrosis interact. However, compared with dcSSc, it is characterized by limited skin fibrosis and relatively prominent vascular changes and autoimmune responses.

Autoimmunity and anti-centromere antibodies: The most characteristic immunological marker of CREST syndrome is anti-centromere antibody (ACA), positive in about 70~80% of patients. ACA targets CENP-A, CENP-B, and CENP-C, component proteins of the centromere. CENP-B is the most commonly measured antigen and is a DNA-binding protein that binds alphoid repeat sequences on chromosome 17. The mechanism of ACA development has not been fully elucidated, but it has been hypothesized that CENP proteins released from vascular endothelial cells or fibroblasts are presented as immunogenic peptides, activating autoreactive B cells and T cells. Beyond being a simple diagnostic marker, ACA plays an important role in predicting capillary loss, development of PAH, and ischemic fingertip complications.

Vascular injury: Endothelial cell injury of small vessels (arterioles·capillaries) is also the initial pathological event in CREST syndrome. As a result of endothelial injury, endothelin-1 (ET-1) secretion increases and nitric oxide (NO)·prostacyclin synthesis decreases, sustaining vasoconstriction and inhibition of angiogenesis. Reactive oxygen species generated during repeated ischemia-reperfusion injury further damage endothelial cells. The capillaroscopy findings of CREST syndrome (giant capillaries, capillary loss) are the result of this chronic vascular injury and an insufficient angiogenic response.

Mechanism of calcinosis: Calcinosis cutis is understood as the result of local tissue injury, cell necrosis, and extracellular matrix degeneration occurring in ischemic tissue. There is a hypothesis that hypoxia-inducible factor (HIF-1α) promotes chondrocyte-like differentiation, causing local calcium·phosphate deposition. Intracellular calcium overload due to mitochondrial dysfunction has also been proposed as a contributing factor. There are studies indicating that TGF-β, BMP (bone morphogenetic protein), and pyrophosphate phosphorylase (deficiency of PPi-synthesizing enzyme) are involved at calcinosis lesion sites, but the exact mechanism of calcinosis has not yet been fully elucidated.

Environmental and triggering factors: As with dcSSc, epidemiological studies have linked occupational silica exposure, organic solvents (such as trichloroethylene) and aromatic hydrocarbons to the onset of lcSSc/CREST as well. Smoking worsens the vascular lesions of CREST syndrome by aggravating Raynaud's phenomenon and vascular endothelial injury. Some drugs (bleomycin, the antibiotic penicillamine) can induce CREST-like skin changes. Regarding endocrine factors, there are epidemiological observations that menopausal hormonal changes are associated with the timing of onset.


3. Genetics

The genetic background of CREST syndrome consists of polygenic susceptibility genes shared with systemic sclerosis as a whole and CREST/lcSSc-specific genotypes. It is not a single-gene defect; a multifactorial genetic model in which multiple gene variants interact with environmental factors to cause disease is accepted.

HLA associations: HLA genotypes associated with anti-centromere antibody (ACA) positivity are the best studied aspect of genetic susceptibility to CREST/lcSSc. HLA-DQB1*05:01 and HLA-DRB1*01:01 have been identified as the risk alleles most strongly associated with ACA-positive systemic sclerosis. HLA-DRB1*04:04 has also been reported in some studies to be associated with lcSSc and ACA. In contrast, HLA-DRB1*11:04, which is associated with dcSSc and anti-Scl-70 antibodies, is not a risk allele in ACA-positive lcSSc; this three-way association pattern of HLA–antibody–clinical subtype is a core concept in systemic sclerosis genomics.

Non-HLA genetic associations: Genome-wide association studies (GWAS) and candidate gene studies have identified several non-HLA gene variants in CREST/lcSSc and in systemic sclerosis as a whole. IRF5 (interferon regulatory factor 5): amplifies the type I interferon response and promotes autoimmune responses. The IRF5 rs2004640 variant is one of the strongest non-HLA risk genes in systemic sclerosis overall. STAT4: mediates interleukin-12, -23 and interferon-γ signaling to enhance Th1 responses; an association has also been reported in ACA-positive patients. TNFSF4 (OX40L): a gene regulating T-cell activation and survival, and a shared risk gene for systemic sclerosis and other autoimmune diseases. CD247: encodes the TCRζ chain and is involved in T-cell receptor signal transduction; abnormal signaling leads to failure to control autoreactive T cells.

Interaction between autoantibodies and genotype: In systemic sclerosis, autoantibody types occur in an almost mutually exclusive manner (if a patient is anti-Scl-70 positive, ACA is usually negative), suggesting that each antibody type reflects a different genotype and immune response pathway. The genetic background of ACA positivity (HLA-DQB1*05:01) is interpreted as being related to a tendency toward a specific immune response against CENP protein epitopes. Because the predictive value of ACA reflects the clinical course of lcSSc (PAH risk, coexisting primary biliary cirrhosis), the autoantibody profile itself serves as genetic risk stratification in clinical practice even without genotype testing.

Genetic overlap with primary biliary cirrhosis (PBC): PBC (current name: primary biliary cholangitis) coexists in about 5% of patients with CREST syndrome (lcSSc), and the two diseases share some susceptibility genes such as HLA-DR8, STAT4 and IRF5. Antimitochondrial antibodies (AMA) are positive when PBC coexists with CREST syndrome, and the genetic and immunological overlap of the two diseases explains why this combination is observed more often than by chance.


4. General epidemiology

CREST syndrome (lcSSc) is the most common clinical subtype of systemic sclerosis, accounting for about 60–70% of all patients with systemic sclerosis. Since the prevalence of systemic sclerosis is about 100–300 per million population, lcSSc is estimated at about 60–200 per million. The incidence is about 5–15 per million population per year, slightly higher than dcSSc.

Sex and age distribution: Like dcSSc, CREST syndrome occurs far more often in women, but studies indicate that the female:male ratio is even higher than in dcSSc, reaching about 4–6:1. Age at onset is concentrated in the 40s–60s, and onset tends to be on average 10 years later than dcSSc. Raynaud's phenomenon often precedes skin sclerosis and visceral findings by decades, so the actual natural history of lcSSc is longer when counted from the onset of Raynaud's phenomenon. Clustering of onset is observed in perimenopausal women, and an immunomodulatory role of estrogen has been proposed.

Autoantibody distribution: Anti-centromere antibody (ACA) is positive in about 70–80% of patients with lcSSc/CREST, the immunological feature that most clearly distinguishes it from dcSSc. ACA-positive patients generally have less severe ILD and a relatively higher risk of PAH. ACA-negative lcSSc patients may be positive for anti-Th/To, anti-PM-Scl, anti-U1-RNP antibodies and others, and prognosis differs according to these antibody profiles.

Epidemiology in Korea: Domestic studies, including data from the Korean KOSC (Korean Systemic Sclerosis Cohort), have reported that the proportion of lcSSc is somewhat lower and the proportion of dcSSc relatively higher than in Western countries, although results vary by study method. The ACA positivity rate in Korean patients with systemic sclerosis tends to be lower than in the West, at about 30–50%, which is related to the relatively higher anti-Scl-70 positivity rate in Asian patients. In Korea, the incidence of PAH in lcSSc patients is also reported at about 10–20%, and PAH is one of the main causes of death in Korean patients with systemic sclerosis.

Comorbidities: In CREST syndrome, the reported rates of coexisting primary biliary cirrhosis (PBC) are about 5%, autoimmune thyroid disease about 15–20%, and overlap with Sjögren's syndrome about 10–15%. These comorbidities require appropriate screening and concurrent management. Pulmonary arterial hypertension (PAH) is a long-term complication of lcSSc that can occur even decades after diagnosis, so continuous surveillance is important.


5. Pathophysiology

The pathophysiology of CREST syndrome shares the vascular injury–autoimmunity–fibrosis triad of systemic sclerosis as a whole, but compared with dcSSc it is characterized by a limited extent of skin fibrosis and more prominent vascular changes and specific autoimmune responses.

Pathogenic role of anti-centromere antibody (ACA): When ACA binds to the centromere proteins CENP-A, CENP-B and CENP-C, spindle formation and chromosome segregation during cell division are disrupted. There is experimental evidence that antigens similar to CENP-B are expressed on endothelial cells and platelets, so direct cytotoxicity or complement activation by ACA may occur. In vitro studies using serum from ACA-positive patients have observed inhibition of endothelial cell proliferation and increased apoptosis. ACA may also damage endothelial cells through ADCC (antibody-dependent cellular cytotoxicity), which partly explains the prominent capillary loss and vascular complications in CREST syndrome.

Mechanism of vascular lesions and calcinosis: After small-vessel endothelial injury, persistent vasoconstriction (excess endothelin-1 secretion, nitric oxide deficiency) creates a state of chronic ischemia. In ischemic tissue, cell necrosis and tissue damage recur, and during this process local mineral deposition occurs, forming calcinosis cutis. Calcinosis is deposited in the dermis and subcutaneous tissue in the form of hydroxyapatite crystals. A mechanism has also been proposed in which BMP-2 and BMP-4 (bone morphogenetic proteins) locally induce chondrocyte or osteocyte differentiation and promote calcium deposition. Impaired intracellular calcium homeostasis due to mitochondrial dysfunction is also known to contribute to the development of calcinosis.

Mechanism of pulmonary arterial hypertension (PAH): In lcSSc/CREST patients, PAH involves a combination of endothelial injury and dysfunction of the pulmonary arterioles, vascular smooth muscle cell proliferation and vascular remodeling. Excess secretion of endothelin-1 stimulates pulmonary vasoconstriction and vascular smooth muscle cell proliferation, increasing pulmonary vascular resistance. Reduced nitric oxide synthase (eNOS) function decreases vasodilation. Abnormal angiogenesis due to aberrant VEGF signaling also contributes to the formation of plexiform lesions. PAH is more common in lcSSc, in which systemic skin fibrosis is less advanced, because vascular lesions are selectively concentrated in the pulmonary vessels.

Mechanism of esophageal dysmotility: Autonomic dysfunction and fibrosis of the esophageal smooth muscle (especially the lower two-thirds) cause impaired esophageal peristalsis and reduced lower esophageal sphincter (LES) function. Vagus nerve damage and loss of interstitial cells of Cajal (ICC) have been proposed as neurological causes of reduced esophageal motility. Gastroesophageal reflux due to reduced LES pressure is a risk factor for mucosal damage, Barrett's esophagus and aspiration pneumonia.


6. Symptoms

The clinical symptoms of CREST syndrome are understood around the five core findings that make up the acronym CREST. Not all five findings appear simultaneously in every patient, and the combination and severity of manifestations vary between individuals.

C — Calcinosis cutis: Calcareous (calcium) nodules are deposited in the skin or subcutaneous tissue at pressure sites such as the fingertips, elbows, knees and around the spine. They range in size from a few mm to several cm and are palpable as hard white or yellowish-white masses at the skin surface. When nodules break through the skin and discharge chalk-like white material (rupture), pain and a risk of secondary infection arise. Calcinosis occurs in about 20–40% of patients, and because symptoms develop slowly it is often discovered after accumulating over a long period.

R — Raynaud's phenomenon: On exposure to cold or emotional stress, the fingers (sometimes the toes, nose and ears) show a triphasic color change of pallor (white) → cyanosis → flushing. It occurs in almost all patients with CREST syndrome and often appears years to decades earlier. Repeated ischemia can progress to fingertip ischemic ulcers, digital pitting scars and, in extreme cases, fingertip gangrene.

E — Esophageal dysmotility: Fibrosis and hypomotility of the lower esophageal smooth muscle cause dysphagia to solids, which is worse for solids than liquids. Gastroesophageal reflux disease (GERD) is common and causes acid regurgitation, heartburn and chronic cough. Repeated reflux is a risk factor for esophagitis, stricture, Barrett's esophagus and aspiration pneumonia. When delayed gastric emptying (gastroparesis) coexists, postprandial fullness, nausea and vomiting also occur.

S — Sclerodactyly: Thickening and hardening of the skin of the fingers; unlike dcSSc, it is confined distal to the MCP joints (fingers only, or fingers + hands). It initially begins as finger swelling and gradually progresses to skin sclerosis; as the fingers become thinner and flexion contractures develop, grip strength and hand function decline. Fingertip ischemia due to sclerodactyly increases the risk of ischemic ulcers.

T — Telangiectasia: Dilated small blood vessels appear on the skin surface as red spots or spider-shaped vessels. They occur mainly on the face (cheeks, nose, lips, tongue), fingers and palms, and may also develop on mucous membranes (oral cavity, esophagus, stomach). Gastrointestinal telangiectasia can be a cause of gastrointestinal bleeding. Telangiectasia tends to be more prominent in lcSSc/CREST than in dcSSc.

Late complications: The most important late complication of CREST syndrome is pulmonary arterial hypertension (PAH), which occurs in about 10–20% of patients. PAH presents with progressive exertional dyspnea, fatigue, chest pain and syncope, and the prognosis is very poor without treatment. In addition, primary biliary cirrhosis (PBC) coexists in about 5% and can progress to fatigue, pruritus, jaundice and liver failure.


7. Signs

The physical signs of CREST syndrome consist of characteristic physical examination findings and ancillary test results corresponding to each of the five CREST findings. Recognizing these findings early through skilled examination is key to reducing diagnostic delay.

Signs of calcinosis cutis: Hard nodules are palpable at pressure sites around the fingertips, elbows and knees. The skin surface is slightly raised with local tenderness, and in ruptured cases traces of discharged calcareous material (chalk-like white material) can be seen. Calcification shadows within soft tissue are confirmed on X-rays of the hands/fingers or soft tissue ultrasound.

Raynaud's phenomenon and vascular signs: Finger color changes can be observed when the hands are immersed in cold water or exposed to a cold environment. Digital pitting scars due to chronic ischemia, ischemic ulcers (especially at the fingertips or over bony prominences of joints), nail loss and, rarely, fingertip gangrene appear. On nailfold capillaroscopy, a systemic sclerosis-specific pattern (SD pattern) is characteristically observed: giant capillaries (giant loops), capillary hemorrhages, capillary loss (avascular areas) and neoangiogenesis. This finding is a 2-point item in the 2013 ACR/EULAR classification criteria.

Signs of telangiectasia: Red spots or spider-shaped vessels are observed on the face, lips, tongue, palms and fingers, and they blanch temporarily when pressed with a glass slide or finger and released (blanching on pressure). They are visually prominent especially when numerous telangiectasias are distributed around the cheeks and nose.

Sclerodactyly and skin signs: The skin of the fingers becomes thick and hard and appears shiny. Finger flexion contractures, fingertip retraction and, in some cases, fingertip ischemic necrosis appear. Facial skin sclerosis may cause reduced glabellar wrinkles, radial perioral furrows and limited mouth opening, but these tend to be milder than in dcSSc.

Laboratory and instrumental findings: ANA positive (about 95%), anti-centromere antibody (ACA) positive (about 70–80%). An isolated reduction in DLCO on pulmonary function testing suggests PAH. Echocardiography: elevated estimated pulmonary artery systolic pressure (sPAP), right heart hypertrophy and dysfunction. Elevated liver enzymes (ALP, GGT) and positive antimitochondrial antibody (AMA) suggest coexisting PBC. Esophageal manometry shows reduced lower esophageal sphincter pressure and loss of esophageal peristalsis.


8. Screening

Because Raynaud's phenomenon is the main early symptom of CREST syndrome, systematic screening of patients presenting with Raynaud's phenomenon as the chief complaint is key to early diagnosis. A regular screening program is also needed to detect major complications such as PAH early in confirmed patients.

Screening of patients with Raynaud's phenomenon: If there are findings suggesting secondary Raynaud's phenomenon (onset after age 40, asymmetric or severe attacks, tissue damage, positive autoantibodies, capillaroscopic abnormalities), immediate specialist referral is needed. A systemic sclerosis-specific autoantibody panel including ANA and anti-centromere antibody (ACA) is performed. Nailfold capillaroscopy is used to confirm the SD pattern. The triad of capillaroscopic abnormality + ACA positivity + Raynaud's phenomenon is strong evidence of "early systemic sclerosis" or CREST syndrome.

PAH screening (confirmed patients): PAH is often unrecognized in its early asymptomatic stage, so systematic screening is essential. According to EULAR recommendations, estimated sPAP is measured by echocardiography every year. An isolated reduction in DLCO on pulmonary function testing (elevated FVC/DLCO ratio) is an early indicator of PAH. The DETECT algorithm combines six noninvasive variables (FVC/DLCO ratio, serum urate, right-axis deviation on ECG, serum NT-proBNP, presence of telangiectasia, presence of anti-centromere antibody) to calculate a PAH suspicion score and determine the indication for right heart catheterization. If sPAP ≥ 40 mmHg or the DETECT score criterion is met, the diagnosis is confirmed by right heart catheterization.

Screening for primary biliary cirrhosis (PBC): In ACA-positive lcSSc patients with fatigue, pruritus or abnormal liver enzymes (especially ALP, GGT), PBC is screened for with antimitochondrial antibody (AMA), AMA-M2, liver biopsy and so on. Regular liver function tests are recommended even in asymptomatic lcSSc patients.

ILD screening: ILD is less common in lcSSc than in anti-Scl-70-positive dcSSc, but the risk of ILD is higher in ACA-negative or anti-Th/To-positive lcSSc. Pulmonary function tests (FVC, DLCO) are performed initially and annually thereafter, and chest HRCT is performed if FVC < 70% or there is a rapid decline.


9. Diagnosis

The diagnosis of CREST syndrome applies the 2013 ACR/EULAR classification criteria for systemic sclerosis and is made through integrated assessment of clinical findings, immunological tests and instrumental tests.

CREST-related findings in the 2013 ACR/EULAR classification criteria: The scoring system includes many of the findings that make up CREST. Telangiectasia 2 points, abnormal nailfold capillaroscopy 2 points, Raynaud's phenomenon 3 points, systemic sclerosis-related autoantibodies such as anti-centromere antibody 3 points, and pulmonary arterial hypertension or ILD 2 points each (maximum 2 points) are the items that particularly score in CREST syndrome. Points for finger skin sclerosis (sclerodactyly) are also included when applicable. A total of 9 points or more meets the classification criteria.

Differential diagnosis: CREST syndrome must be differentiated from primary Raynaud's disease, dcSSc, mixed connective tissue disease (MCTD) and primary Raynaud's disease. MCTD is distinguished by positive anti-U1-RNP antibody, hand swelling, arthritis, myositis and multi-organ involvement. Localized scleroderma (morphea) shows only localized skin lesions without systemic symptoms or autoantibodies. Calcinosis can also occur in dermatomyositis, gout and pseudogout, so it is differentiated in the overall clinical context.

Initial assessment after confirmed diagnosis: As a baseline assessment after confirmation, echocardiography (PAH baseline), pulmonary function (FVC, DLCO), chest HRCT (ILD baseline), esophageal manometry and endoscopy (extent of esophageal involvement), liver function and AMA (coexisting PBC), hand and foot X-rays (extent of calcinosis) and mRSS (skin sclerosis score) are performed. The initial assessment serves as the reference for subsequent monitoring of progression.

Confirmation of PAH: Right heart catheterization (RHC) is used to confirm a resting mean pulmonary artery pressure (mPAP) ≥ 20 mmHg, pulmonary capillary wedge pressure (PCWP) ≤ 15 mmHg and pulmonary vascular resistance (PVR) ≥ 2 Wood units (revised 2022 ESC/ERS criteria). Unlike idiopathic PAH, SSc-PAH has a low response rate on vasoreactivity testing (vasodilator test), so long-term calcium channel blocker monotherapy is not indicated.


10. Treatment

Treatment of CREST syndrome follows an organ-specific approach tailored to each of the five CREST findings and the late complications (PAH, PBC). There is no curative treatment, and the goals of treatment are symptom control, preservation of organ function and prevention of complications.

Treatment of Raynaud's phenomenon: Nonpharmacological measures (avoiding cold, warm gloves and socks, smoking cessation) are fundamental. First-line drugs: long-acting calcium channel blockers (CCBs) — amlodipine (2.5–10 mg/day), nifedipine (extended-release 30–60 mg/day). Second-line drugs: PDE-5 inhibitors (sildenafil 20–60 mg/day, tadalafil 5–20 mg/day) are effective for severe Raynaud's phenomenon and ischemic ulcers. Bosentan (endothelin receptor antagonist): approved for the prevention of new ischemic digital ulcers. Bosentan has limited healing effect on ulcers that have already formed. Topical nitroglycerin ointment, cilostazol and antiplatelet agents are also considered as adjuncts. In extreme cases, intravenous prostanoids (iloprost), sympathetic blockade and digital sympathectomy are also options.

Treatment of pulmonary arterial hypertension (PAH): SSc-PAH requires aggressive treatment as soon as it is detected. First choice: combination of an endothelin receptor antagonist (ERA) + PDE-5 inhibitor is recommended from the outset (based on the AMBITION trial). ERAs: ambrisentan (5–10 mg/day), macitentan (10 mg/day), bosentan (62.5→125 mg twice/day). PDE-5 inhibitors: sildenafil (20 mg 3 times/day), tadalafil (40 mg/day). sGC stimulator: riociguat (0.5→2.5 mg 3 times/day) can be combined with an ERA but is contraindicated in combination with PDE-5 inhibitors. Prostacyclin analogues: selexipag (oral), iloprost (inhaled) and epoprostenol (intravenous, most severe cases) are added stepwise. Warfarin anticoagulation is generally not recommended in SSc-PAH because, unlike idiopathic PAH, no survival benefit has been demonstrated.

Gastrointestinal (esophageal) treatment: Proton pump inhibitors (PPIs, such as omeprazole and pantoprazole) are given at high doses long term. Correction of eating posture (no lying down for 2–3 hours after meals), small frequent meals, and restriction of foods that worsen reflux (alcohol, caffeine, fat, chocolate). For delayed gastric emptying, short-term use of metoclopramide or domperidone. Endoscopic dilation if esophageal stricture develops. For bacterial overgrowth, rotating antibiotic therapy (alternating ampicillin, metronidazole, doxycycline) is given.

Treatment of calcinosis cutis: There is no established standard treatment, and the level of evidence for various drugs and procedures is low. Colchicine (0.5–1 mg/day), low-dose warfarin and diltiazem (a calcium channel blocker) have been reported in small studies to reduce the size of calcinosis. There are case reports on isotretinoin, aluminum hydroxide and bisphosphonates. For painful or infected lesions, surgical excision, laser therapy (CO2 laser) and extracorporeal shock wave lithotripsy (ESWL) are performed selectively. If secondary infection develops from ruptured calcinosis, topical or systemic antibiotics are given.


11. Prognosis

The prognosis of CREST syndrome (lcSSc) is generally better than that of diffuse systemic sclerosis (dcSSc), but it worsens sharply when certain complications such as PAH develop. Long-term follow-up after diagnosis and active early detection of complications are key to improving survival.

Survival: The 10-year survival of lcSSc is about 75–85%, better than dcSSc (about 55–70%). However, when PAH develops, mortality within 2–3 years without treatment is very high, and there are reports that even after the introduction of modern targeted therapies, 5-year survival of SSc-PAH is only about 50–60%. ILD is less common and progresses more slowly in lcSSc, but in severe cases it worsens the prognosis.

Major prognostic factors: Occurrence and severity of PAH, anti-centromere antibody positivity (predicting PAH risk), initial FVC/DLCO ratio, age (poorer in older patients), male sex (poorer than in women) and coexisting PBC affect the prognosis of lcSSc. Skin involvement is confined to the fingers and hands, so compared with dcSSc there is less loss of joint function and functional impairment due to skin complications is milder. Calcinosis does not have a large direct effect on survival, but it greatly reduces quality of life through chronic pain, infection and reduced hand function.

Quality of life: Raynaud's attacks, limited hand function (sclerodactyly, calcinosis), esophageal symptoms (reflux, dysphagia), limited mouth opening, chronic pain and changes in skin appearance (telangiectasia, pigment changes) affect daily activities and social functioning. Depression and anxiety are common, and psychosocial support is important. Reduced systemic sclerosis-related health-related quality of life (HRQoL) has also been reported in Korean patients, and integrated management by a multidisciplinary rheumatology team is needed.

Follow-up plan: Echocardiography (PAH screening), pulmonary function (FVC, DLCO) and liver function tests (PBC screening) are performed annually. Patients with confirmed PAH undergo clinical assessment, 6-minute walk test, serum NT-proBNP and echocardiography every 3–6 months. Worsening esophageal symptoms, new respiratory symptoms, sudden changes in blood pressure and the like are evaluated immediately. Registration for Korea's Special Copayment Reduction (V138) is used to obtain reduced medical costs.


12. Prevention

There is no complete primary prevention that prevents the onset of CREST syndrome itself; the prevention strategy consists of three stages: risk factor control, early diagnosis and prevention of complications.

Primary prevention (reducing the risk of onset): Occupational health management to minimize exposure to occupational silica, organic solvents and aromatic hydrocarbons is recommended. Smoking worsens Raynaud's phenomenon and vascular complications, so smoking cessation is essential. Cold exposure triggers Raynaud's attacks, so education on protection from cold is important. Correction of vitamin D deficiency, a healthy diet and weight maintenance, and regular aerobic exercise are recommended for maintaining overall health.

Secondary prevention (early detection): In adults with new-onset Raynaud's phenomenon, ANA, systemic sclerosis-specific autoantibodies and nailfold capillaroscopy are performed early. If the combination of ACA positivity + capillaroscopic abnormality + Raynaud's phenomenon is present, immediate specialist referral and baseline assessment of visceral involvement are performed. After confirmation, a systematic screening program for PAH, ILD and PBC is started immediately.

Tertiary prevention (suppressing progression of complications): In confirmed patients, annual echocardiography and PFTs and application of the DETECT algorithm are continued for early detection of PAH. Active vasodilator treatment of Raynaud's phenomenon suppresses fingertip ischemic ulcers and worsening of calcinosis. Long-term PPI therapy for GERD prevents esophageal complications (stricture, Barrett's esophagus, aspiration). Regular oral care (dental treatment in anticipation of limited mouth opening), physical and occupational therapy (maintaining hand function) and nutritional counseling (preventing malabsorption and weight loss) are provided in an integrated manner. Methods of cold avoidance (warm gloves, heated gloves, maintaining room temperature) are taught thoroughly.


13. References

  1. Velayos EE, Masi AT, Stevens MB, et al. The 'CREST' syndrome. Comparison with systemic sclerosis (scleroderma). Semin Arthritis Rheum. 1979;9(1):37-51. DOI: 10.1016/0049-0172(79)90026-9. PMID: 400863.

  2. van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis. Arthritis Rheum. 2013;65(11):2737-2747. DOI: 10.1002/art.38098. PMID: 24122180.

  3. Coghlan JG, Denton CP, Gruenig E, et al. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis. 2014;73(7):1340-1349. DOI: 10.1136/annrheumdis-2013-203305. PMID: 23687283.

  4. Galie N, Channick RN, Frantz RP, et al. Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respir J. 2019;53(1):1801889. DOI: 10.1183/13993003.01889-2018. PMID: 30545972.

  5. Denton CP, Hughes M, Gak N, et al. BSR and BHPR guideline for the treatment of systemic sclerosis. Rheumatology (Oxford). 2016;55(10):1906-1910. DOI: 10.1093/rheumatology/kew224. PMID: 27117700.

  6. Koenig M, Joyal F, Fritzler MJ, et al. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis. Arthritis Rheum. 2008;58(12):3902-3912. DOI: 10.1002/art.24038. PMID: 19035499.

  7. Wigley FM, Flavahan NA. Raynaud's phenomenon. N Engl J Med. 2016;375(6):556-565. DOI: 10.1056/NEJMra1507638. PMID: 27509103.

  8. Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390(10103):1685-1699. DOI: 10.1016/S0140-6736(17)30933-9. PMID: 28413064.

  9. Khanna D, Denton CP, Jahreis A, et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet. 2016;387(10038):2630-2640. DOI: 10.1016/S0140-6736(16)00232-4. PMID: 27156903.

  10. Kim GT, Kim J, Lee J, et al. Clinical features and organ damage in Korean patients with systemic sclerosis. J Korean Med Sci. 2021;36(10):e75. DOI: 10.3346/jkms.2021.36.e75. PMID: 33724741.